Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-380, HER2 inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-380 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-380, HER2 inhibitor; oral | DRUG | Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule. |
Key Inclusion Criteria (Part 1 and Part 2): * Histological or cytological evidence of HER2+ cancer (Part 1) or HER2+ metastatic breast cancer (Part 2). * Patients should have received at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standar...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | Durvalumab |
| Nanobiotix SA Sponsored ADR | NBTX | 1 | PHASE1 | NBTXR3 |
| Olema Pharmaceuticals, Inc. | OLMA | 1 | PHASE1 | OP-3136, Palazestrant |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
| Pfizer Inc. | PFE | 1 | N/A | Palbociclib |
ARRY-380 is an investigational small molecule being studied for the treatment of advanced HER2-positive cancer. It is being developed by Pfizer, Inc. (ticker: PFE) and is currently in Phase 1 clinical development. The drug is designed to target HER2, a protein that is overexpressed in certain cancers, and is being evaluated in patients with advanced HER2+ tumors.
ARRY-380 targets HER2, a receptor tyrosine kinase that is overexpressed in some cancers. By inhibiting HER2, ARRY-380 may block signaling pathways that drive tumor growth. This mechanism is being explored in patients with advanced HER2-positive cancer as part of its clinical development.
ARRY-380 is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer is responsible for the clinical development of this oral HER2 inhibitor, which is currently in Phase 1 testing for advanced HER2-positive cancer.
ARRY-380 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 trial, NCT00650572, has been completed and enrolled 50 patients with advanced HER2-positive cancer.
ARRY-380 has been studied in one completed Phase 1 clinical trial, NCT00650572, titled "A Study of ARRY-380 in Patients With Advanced HER2+ Cancer." The trial enrolled 50 patients across the United States and Canada and was an uncontrolled, non-randomized study in adults with advanced HER2-positive cancer.
Yes, ARRY-380 is also known as ARRY-380, HER2 inhibitor, and is sometimes referred to as oral ARRY-380. These names refer to the same investigational drug candidate being developed by Pfizer for advanced HER2-positive cancer.